Get the Stockscreener App
8.185
0.22%
0.005
Oric Pharmaceuticals Inc stock is traded at $8.185, with a volume of 442.77K.
It is up +0.22% in the last 24 hours and down -23.03% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$8.18
Open:
$8.24
24h Volume:
442.77K
Relative Volume:
0.33
Market Cap:
$797.13M
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-4.3307
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
-0.63%
1M Performance:
-23.03%
6M Performance:
-23.03%
1Y Performance:
-0.75%
1-Day Range:
$8.04
$8.33
1-Week Range:
$7.955
$8.44
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.185 | 796.64M | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.79 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.65 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.40 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.72 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.51 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cuts2025 Market WrapUp & Reliable Trade Execution Plans - Улправда
Market Overview: How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsWatch List & Safe Entry Trade Reports - Улправда
Why ORIC Pharmaceuticals Inc. stock attracts global investorsM&A Rumor & Growth Focused Investment Plans - DonanımHaber
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
How strong is ORIC Pharmaceuticals Inc. stock revenue growth2025 Momentum Check & AI Powered Market Entry Ideas - Улправда
ORIC Pharmaceuticals Earnings Notes - Trefis
Oric Pharmaceuticals (NASDAQ:ORIC) Insider Pratik Multani Sells 10,720 Shares - MarketBeat
Dominic Piscitelli Sells 10,720 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells 33,374 Shares - MarketBeat
[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Oric Pharmaceuticals Executives Conduct Stock Transactions - TradingView — Track All Markets
Oric Pharmaceuticals President and CEO Sells Shares - TradingView — Track All Markets
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.5%Here's What Happened - MarketBeat
CFO Piscitelli Files To Sell 10,720 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value - Insider Monkey
20 Stocks That Will Double in 2026 - Insider Monkey
Frazier Life Sciences Management L.P. Sells 344,859 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals Advances Key Cancer Drug Toward Late-Stage Trials - AD HOC NEWS
Oric Pharmaceuticals, Inc. $ORIC Shares Sold by EcoR1 Capital LLC - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
Stempoint Capital LP Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Dir Kunkel Acquires 10,000 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
Vivo Capital LLC Has $31.74 Million Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Resolute Capital Asset Partners LLC Invests $2.31 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Wells Fargo maintains ORIC Pharmaceuticals (ORIC) overweight recommendation - MSN
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Analyst Rating Update from Wells Fargo | ORIC Stock News - GuruFocus
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wedbush Reiterates 'Outperform' Rating for ORIC Pharmaceuticals - GuruFocus
Wells Fargo raises ORIC Pharmaceuticals stock price target on promising cancer drug data - Investing.com Canada
Oric Pharmaceuticals, Inc. Presents Enozertinib Program Update - TradingView
JPMorgan Chase & Co. Raises Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals (ORIC) Showcases Promising Phase 1b Trial D - GuruFocus
Oric Pharmaceuticals presents data from enozertinib trial at ESMO Asia - MSN
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 - Sahm
Fund Flows: Will ORIC Pharmaceuticals Inc stock see PE expansionPortfolio Growth Summary & Growth Focused Investment Plans - moha.gov.vn
Head to Head Survey: Oric Pharmaceuticals (NASDAQ:ORIC) & LENZ Therapeutics (NASDAQ:LENZ) - Defense World
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - The Manila Times
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Multani Pratik S | Chief Medical Officer |
Dec 16 '25 |
Sale |
9.06 |
10,720 |
97,129 |
68,149 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '25 |
Option Exercise |
0.00 |
29,333 |
0 |
78,868 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '25 |
Sale |
9.06 |
10,720 |
97,127 |
68,148 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '25 |
Option Exercise |
0.00 |
83,666 |
0 |
615,085 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '25 |
Sale |
9.06 |
33,374 |
302,368 |
581,711 |
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):